| Literature DB >> 36124147 |
Chiara Fusi1, Pietro Enea Lazzerini2, Luna Cavigli1, Marta Focardi1, Maurizio Acampa3, Matteo Cameli1, Serafina Valente1, Flavio D'Ascenzi1.
Abstract
Prolongation of the PR interval is common among competitive athletes. However, further investigations should be performed when the PR interval is markedly prolonged. We report the case of a young male athlete with an autoimmune-mediated atrioventricular block due to circulating anti-Ro/SSA-antibodies in the mother (late progressive congenital form). (Level of Difficulty: Advanced.).Entities:
Keywords: AV, atrioventricular; ECG, electrocardiogram; anti-Ro/SSA, anti-Sjögren-syndrome-related antigen A antibodies; autoimmune; bradycardia; electrocardiogram; exercise; immunization
Year: 2022 PMID: 36124147 PMCID: PMC9481900 DOI: 10.1016/j.jaccas.2022.05.032
Source DB: PubMed Journal: JACC Case Rep ISSN: 2666-0849
Figure 112-Lead Resting Electrocardiogram at Presentation
Resting heart rate of 75 beats/min, PR interval of 400 ms, and incomplete right bundle branch block.
Figure 212-Lead Resting Electrocardiogram at Age 10 Years
PR interval of 400 ms.
Figure 312-Lead 24-Hour Ambulatory Electrocardiogram Monitoring
Shortening of PR interval during the training session.
Congenital and Acquired Causes of Atrioventricular Block in the Young
| Congenital | Acquired |
|---|---|
| Autoimmunity (anti-Ro/SSA-associated): congenital, late progressive congenital | Inflammatory: myocarditis, endocarditis, acute rheumatic fever, Lyme carditis, systemic lupus erythematosus and other CTDs, spondyloarthritis |
Anti-Ro/SSA = anti-Sjögren-syndrome-related antigen A antibodies; CTDs = connective tissue diseases.
Autoimmune (Anti-Ro/SSA-Associated) atrioventricular Blocks
| Clinical Characteristic | Congenital | Late Progressive Congenital | Acquired |
|---|---|---|---|
| Mother/child immunologic findings | Circulating anti-Ro/SSA in the mother and in the patient | Circulating anti-Ro/SSA in the mother (not in the patient) | Circulating anti-Ro/SSA in the patient (not in the mother) |
| Incidence | 1 in 15,000-25,000 live births | Not well known (possibly at least 10% of all cases of isolated 3° AVB of unknown origin in adults) | Not well known (possibly at least 10% of all cases of isolated 3° AVB of unknown origin in adults) |
| Age at onset | In utero/at birth/within the neonatal period (0-27 days) | Childhood/adulthood | Adulthood |
| Presentation | Progressively developing conduction disturbances (early phase: reversible 1° and 2° AVB; final phase: irreversible congenital 3°AVB) | Subclinical AV node damage during the fetal/neonatal period; late first diagnosis of AVB during childhood or adult age | Unexplained (idiopathic) AVB in the adult age |
| Clinical concerns | 15%-30% mortality rate, mostly in utero/early postnatal life | Worsening of AVB with age (accelerated conduction system senescence) | Pacemaker implantation may be avoided or delayed |
| Response to therapy | Complete AVB in the fetus is almost always irreversible; IVIG and fluorinated steroids can prevent progression to 3°AVB | Immunosuppressive treatment is ineffective. | Responsive to immunosuppressive therapy |
anti-Ro/SSA = anti-Sjögren-syndrome-related antigen A antibodies; AV = atrioventricular; AVB = atrioventricular block; IVIG = intravenous immunoglobulins.
Figure 412-Lead Resting Electrocardiogram After 3 Months of Detraining
No significant variation in PR interval.